Medicine
Recarbrio 500 mg/500 mg/250 mg per 100 mL powder for injection
Recarbrio 500 mg/500 mg/250 mg per 100 mL powder for injection is a prescription medicine containing Cilastatin, Imipenem and Relebactam for intravenous use, marketed by Merck Sharp & Dohme, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.
Availability
Export supply from India to licensed buyers
Typical lead time
On request
Counted from payment and complete documents
Shipping
Ambient
Store RECARBRIO vials at 20°C to 25°C (68°F to 77°F), excursions permitted…
Key facts
- Active ingredient (INN)
- Cilastatin, Imipenem and Relebactam
- Brand
- Recarbrio
- Strength
- 500 mg/500 mg/250 mg per 100 mL
- Dosage form
- Powder for injection
- Route
- Intravenous
- Packs
- 25 vials
- Marketing authorisation holder
- Merck Sharp & Dohme
- Manufacturer
- Merck Sharp & Dohme
- Origin register
- US FDA, United States
- Storage
- Store RECARBRIO vials at 20°C to 25°C (68°F to 77°F), excursions permitted between 15°C to 30°C (between 59°F to 86°F).
- Cold chain
- Not required on record
- Prescription status
- Prescription only
- Controlled substance
- Not recorded as controlled
- ATC code
- J01DH56 Cilastatin, Imipenem and Relebactam
- HS code (indicative)
- 3004.20Indicative only. Your customs broker confirms the final tariff code.
- Marketing category
- marketed
- Marketed since
- 6 January 2020
- Identifiers
- RxCUI 2184142, 2184147DailyMed set ID be32f468-738b-40df-a425-591e12f65159NDC 0006-3856Application NDA212819
Record updated 12 November 2026
Documents available
Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.
No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.
Packs
| Pack | Code | Labeler | Marketed since |
|---|---|---|---|
| 25 vial, single-dose in 1 carton / 20 mL in 1 vial, single-dose | 0006-3856-02 | Merck Sharp & Dohme | 6 January 2020 |
Status by register
Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.
Import route
Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.
Import guides are available for 25 countries. Pick one to see its route summary.
BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides
Clinical summary
Cilastatin, Imipenem and Relebactam is a fixed-dose combination of a penem antibacterial, a renal dehydropeptidase inhibitor and a beta lactamase inhibitor. It is available as powder for injection for intravenous use. MedsAcross supplies Cilastatin, Imipenem and Relebactam for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
Read about Cilastatin, Imipenem and RelebactamFor healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
Data sources
- DailyMed label record · Checked 12 November 2026
- RECARBRIO prescribing information (Merck Sharp & Dohme) · U.S. National Library of Medicine, DailyMed
- Recarbrio: European public assessment report (EPAR) · European Medicines Agency
Need Recarbrio 500 mg/500 mg/250 mg per 100 mL powder for injection for your hospital or patient?
Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.